Patent · US Active

Coagulation factor X polypeptides with modified activation properties

US9249404B2 · kind B2 · utility

0Cited by

5References

9Claims

0Family size

Assignee

CSL Behring AG · DE

Inventors

Stefan Schulte · Marburg, DE
Hans-Peter Hauser · Marburg, DE
Uwe Kalina · Marburg, DE
Thomas Weimer · Gladenbach, DE

Key dates

Filing date	May 30, 2006
Grant date	Feb 2, 2016
Priority date	—
Expiry date	Aug 24, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21006
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives which have biological activities of the unmodified wild type protein but with improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.